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Abstract
Genomic hypomethylation is a consistent finding in both human and animal tumors and mounting
experimental evidence suggests a key role for epigenetic events in tumorigenesis. Furthermore, it
has been suggested that early changes in DNA methylation and histone modifications may serve as
sensitive predictive markers in animal testing for carcinogenic potency of environmental agents.
Alterations in metabolism of methyl donors, disturbances in activity and/or expression of DNA
methyltransferases, and presence of DNA single-strand breaks could contribute to the loss of cytosine
methylation during carcinogenesis; however, the precise mechanisms of genomic hypomethylation
induced by chemical carcinogens remain largely unknown. This study examined the mechanism of
DNA hypomethylation during hepatocarcinogenesis induced by peroxisome proliferators
WY-14,643 (4-chloro-6-(2,3-xylidino)-pyrimidynylthioacetic acid) and DEHP (di-(2-ethylhexyl)
phthalate), agents acting through non-genotoxic mode of action. In the liver of male Fisher 344 rats
exposed to WY-14,643 (0.1% (w/w), 5 months), the level of genomic hypomethylation increased by
~2-fold, as compared to age-matched controls, while in the DEHP group (1.2% (w/w), 5 months)
DNA methylation did not change. Global DNA hypomethylation in livers from WY-14,643 group
was accompanied by the accumulation of DNA single-strand breaks, increased cell proliferation, and
diminished expression of DNA methyltransferase 1, while the metabolism of methyl donors was not
affected. In contrast, none of these parameters changed significantly in rats fed DEHP. Since
WY-14,643 is much more potent carcinogen than DEHP, we conclude that the extent of loss of DNA
methylation may be related to the carcinogenic potential of the chemical agent, and that accumulation
of DNA single-strand breaks coupled to the increase in cell proliferation and altered DNA
methyltransferase expression may explain genomic hypomethylation during peroxisome
proliferator-induced carcinogenesis.
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Recent developments in clinical and experimental cancer research show that cancer
development is affected not only by changes to DNA sequence [1], but also by the alterations
of the cellular epigenome [2]. Genomic hypomethylation is a consistent finding in human
tumors [3], including liver cancer [4,5]. Aberrant patterns of DNA methylation and/or
modification of histones have been also observed with both genotoxic and non-genotoxic
environmental agents [6–8] and mounting evidence suggests that epigenetic events may be
crucial in the mode of action of various carcinogenic chemicals [9]. It was also suggested that
epigenetic changes should be used as sensitive predictive indicators in the studies on the
mechanism and prognosis of human tumors [10,11], as well as in assessment of the
carcinogenic potential of environmental chemicals since changes in DNA methylation and
histone modifications usually precede the development of pre-carcinogenic lesions [12,13].
The latter has a special significance for non-genotoxic agents, considering the fact that many
carcinogens presented to regulatory agencies today act via non-genotoxic mode of action
[14].
Peroxisome proliferators, a structurally diverse group of chemicals and therapeutic agents, are
one of the most extensively studied classes of non-genotoxic carcinogens [15]. Long-term
exposure to these agents results in the development of liver tumors in male and female mice
and rats [16,17]. Peroxisome proliferators are thought to cause liver cancer in rodents via a
complex mode of action which involves activation of the peroxisome proliferator-activated
receptor α(PPARα) which leads to changes in transcription of many metabolism genes, increase
in size and amount of peroxisomes in liver parenchymal cells, increased hepatocellular
proliferation, suppression of apoptosis, and secondary oxidative stress leading to DNA damage
[18]. In addition, recent evidence suggests that epigenetic events, such as progressive global
hypomethylation of liver DNA, decrease in trimethylation of histone H4 lysine 20 and H3
lysine 9, and a gradual loss of cytosine methylation in major and minor satellites and other
repetitive elements may play a role in the mechanism of the carcinogenic action of a model
peroxisome proliferator WY-14,643 [19].
Since it has been suggested that a carcinogenic potency of the chemical may be related to its
effects on DNA methylation patterns in target tissue [20], better understanding of the molecular
effects leading to dysregulation in maintenance of genome methylation may provide important
clues into both timing and causality of carcinogenesis. Several mechanisms for the
carcinogenic agent-induced genomic hypomethylation have been suggested. These include
alterations in cellular one-carbon metabolism [7,11,12], changes in expression and/or activity
of DNA methyltransferases [21], increased cell proliferation [7,9], and DNA damage [22].
Since little is known about how non-genotoxic rodent liver carcinogens cause changes in DNA
methylation, this study was conducted to define the underlying mechanisms of DNA
hypomethylation by comparing the effects of WY-14,643 and DEHP. We show that
accumulation of DNA single-strand breaks coupled to the increase in cell proliferation and
diminished DNA methyltransferase expression may explain genomic hypomethylation during
peroxisome proliferator-induced liver carcinogenesis and that the extent of loss of DNA
methylation may be related to the carcinogenic potential of the chemical agent.
2. Materials and methods
2.1. Animals and diets
The studies detailed herein were performed using archived liver tissue samples (stored at −80
°C) from previously reported animal studies [23]. Briefly, male F344 rats, 10 weeks of age,
were obtained from Charles River Breeding Laboratories (Raleigh, NC). Rats were housed in
polycarbonate cages in a facility with automatically controlled temperature (22 °C), humidity
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(50%) and light (12 h light/12 h dark cycle). Rats were randomly assigned to three dietary
exposure groups beginning at 12 weeks of age: WY-14,643 (0.1% (w/w), ChemSyn Science
Labs, Lenexa, KS), DEHP (1.2% (w/w), Eastman Chemical Company, Kingsport, TN), or
control. All diets were mixed using NIH-07 diet (Ziegler Brothers, Gardners, PA). Diets were
analyzed for chemical after mixing and used if the actual concentration was within 20% of
target concentration. Following 22 weeks of ad libitum feeding, rats were killed by
exsanguinations following deep isoflurane anesthesia. The livers were excised and frozen
immediately in liquid nitrogen, and stored at −80 °C for subsequent analyses. All animal
experimental procedures were reviewed and approved by the Institutional Animal Care and
Use Committee.
2.2. Assessment of epigenetic changes and DNA strand breaks in liver
The extent of global DNA methylation was evaluated using a radiolabeled [3H]dCTP extension
assay as described elsewhere [24]. The methylation status of the promoter region of the
glutathione-s-transferase placental form (Gstp) gene was determined by the methylation-
sensitive PCR-based assay as previously described [25]. Specifically, genomic DNA was
isolated and digested with methylation-sensitive restriction endonuclease AciI, HpaII, or BstUI
followed by PCR amplification of a 168 bp fragment of the Gstp promoter region. The recovery
of PCR product is varied directly with the extent of AciI-, HpaII-, or BstUI-induced DNA
breaks at unmethylated CCGC, CCGG, or CGCG sites, respectively. The quantitative aspect
of the procedure was verified by a linear increase in the PCR product recovery with increasing
cycle number and DNA template concentration. The results were reproduced in two
independent experiments with all samples.
The determination of s-adenosylmethionine (SAM) and s-adenosylhomocysteine (SAH)
content in liver tissue extracts was performed by a HPLC method with coulometric
electrochemical detection as previously described [26]. DNA strand breaks were detected using
random oligonucleotide-primed synthesis assay as described previously [27].
2.3. Western blot analysis of protein expression and histone modifications
The liver protein levels of DNA methyltransferase 1 (DNMT1), proliferating cells nuclear
antigen (PCNA), c-Myc, and β-actin were determined by Western immunoblotting. Briefly,
liver tissue lysates were prepared by homogenization of 50 mg of tissue in 500 μl of lysis buffer
(50 mM Tris–HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM
EDTA; 1 mM PMSF; 1 μg/ml each aprotinin, leupeptin, pepstatin; 1 mM Na3 VO4, 1 mM
NaF), sonication, and incubation at 4 °C for 30 min, followed by centrifugation at 10,000 ×
g at 4 °C for 20 min. Protein concentration was determined by the Bradford assay (Pierce,
Rockford, IL). Extracts containing equal quantities of proteins were separated by SDS-PAGE
on 8 or 10% polyacrylamide gels and transferred to PVDF membranes (Millipore, Billerica,
MA). Membranes were probed with primary antibodies against DNMT1 (1:500; Abcam,
Cambridge, MA), PCNA (1:300; Santa Cruz Biotechnology, Santa Cruz, CA), c-Myc (1:200;
Santa Cruz Biotechnology), or β-actin (1:500; Santa Cruz Biotechnology). Alkaline
phosphatase-coupled donkey anti-rabbit secondary antibodies were used for visualization.
Signals were quantified using ImageQuant 5.1 software (Molecular Dynamics, Sunnyvale, CA)
and normalized relative to β-actin. The status of histone H3 lysine 9 trimethylation (H3K9me3)
and histone H4 lysine 20 trimethylation (H4K20me3) was determined by Western blot analysis
as described previously [19].
2.4. Statistical analysis
Results are presented as mean ± S.D. and were assessed by one-way ANOVA, using treatment
as the fixed factor. P-values < 0.05 were considered significant.
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3.1. DNA methylation status
Rapid and progressive hypomethylation of DNA has been reported to occur in the livers of
mice fed a WY-14,643-containing diet both acutely [28], and chronically for up to 5 months
[19]. In this study, we aimed to determine whether similar effects can be observed in other
species susceptible to hepatocarcinogenesis by WY-14,643 (i.e., rats), as well as to compare
the effects of a potent, such as WY-14,643 [29], and weak, such as DEHP [29],
hepatocarcinogens. Dietary feeding of F344 rats with a WY-14,643-containing diet for 5
months resulted in substantial hypomethylation of genomic DNA in the liver at CCGG
sequences (Fig. 1, top panel). In contrast, administration of a DEHP-containing diet for 5
months had no appreciable effect on the methylation status of hepatic DNA.
Since the majority of cytosine methylation in mammalian cells resides mainly in the GC-rich
regions of repetitive elements [30] and alterations in methylation of these regions have been
mechanistically linked to tumor formation [7,31,32], we assessed the methylation status of the
GC-rich domains following exposure to WY-14,643 and DEHP. The long-term exposure to
WY-14,643, but not DEHP, resulted in the hypomethylation of the GC-rich DNA regions,
evident from an increase in [3H]dCTP incorporation into BssHII- or AscI-digested DNA (Fig.
1, middle and bottom panels).
Global DNA hypomethylation, in addition to hypomethylation of repetitive sequences, is
frequently associated with the hypomethylation of normally methylated CpG islands in gene
promoters [33]. Indeed, the results of our previous study demonstrated that loss of global DNA
methylation during rat hepatocarcinogenesis was accompanied by hypomethylation of
normally methylated-specific CpG sites in the promoter region of the Gstp gene [34]. Because
of this association, we assessed the status of Gstp promoter methylation in the livers of control
rats and rats exposed to WY-14,643 or DEHP (Fig. 2). WY-14,643, but not DEHP, caused a
substantial loss of cytosine methylation at AciI and HpaII sites normally methylated in the
Gstp promoter, as evidenced by a decrease in the PCR product recovery after pre-treatment of
DNA with methylation-sensitive restriction endonucleases AciI or HpaII.
3.2. Histone H3K9 and H4K20 methylation
When WY-14,643 was fed in the diet to mice, trimethylation of histone H4K20 and H3K9 was
significantly decreased in liver as early as 1 week of treatment and persisted for the duration
of the experiments for up to 5 months [19]. Interestingly, in this study conducted in the rat at
comparable dose and duration of treatment, no changes in the extent of trimethylation of
histones H3K9 and H4K20 was observed in the liver in animals exposed to either DEHP or
WY-14,643 (Fig. 3).
3.3. SAM and SAH content
One of the main factors assuring the proper maintenance of DNA methylation is the cellular
availability of methyl groups [11]. To determine whether WY-14,643-induced
hypomethylation of DNA is associated with alterations in the cellular one-carbon metabolic
pathways, hepatic content of SAM and SAH was measured in the livers of WY-14,643- and
DEHP-treated and control rats. Fig. 4 shows that neither WY-14,643, nor DEHP had an effect
on the intracellular concentrations of SAM and SAH in rat liver.
3.4. Expression of DNMT1 and PCNA proteins
DNMT1 is the main cellular enzyme responsible for the maintenance of DNA methylation
patterns in somatic mammalian cells and disruption in its activity and/or expression may lead
to alterations in DNA methylation [21]. Therefore, we assessed the effect of long-term exposure
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to WY-14,643 and DEHP on the levels of the DNMT11 protein in rat liver. Fig. 5 shows that
long-term continuous exposure of F344 rats to WY-14,643 resulted in a decrease in the protein
levels of DNMT1. In contrast, exposure to DEHP led to up-regulation of DNMT1.
Exposure or Fisher 344 rat to WY-14,643 or DEHP for 22 weeks in identical doses is known
to lead to about 60% increase in liver to body weight ratio [35]. Fig. 5 shows that long-term
exposure to WY-14,643 resulted in an increase in liver PCNA protein expression by 40% as
compared to control animals. In contrast, PCNA expression was not affected by DEHP.
The observed up-regulation of the PCNA in the livers of WY-14,643-treated rats and the results
of recent findings by Dominguez-Sola et al. [36] suggesting that c-Myc has a direct role in the
control of DNA replication, prompted us to investigate expression of c-Myc protein in the
livers of rats exposed to WY-14,643 and DEHP. Fig. 5 shows that long-term administration
of WY-14,643 resulted in the pronounced 2.7-fold up-regulation of c-Myc in the rat liver as
compared to control rats. The level of c-Myc was also increased, albeit to a lesser extent, in
DEHP-exposed rats.
3.5. DNA damage
In addition to the availability of methyl group donors, functioning of DNA methyltransferases,
and cell proliferation, another important and frequently overlooked factor that determines the
proper maintenance of the DNA methylation patterns is the integrity of genomic DNA. When
integrity of DNA is compromised, particularly caused by oxidation, methylation efficiency of
cytosine residues is thought to be impacted [37,38]. Indeed, oxidative stress and oxidative
damage to DNA are recognized as one of the mechanisms for the carcinogenic effects of
peroxisome proliferators [39]. We have previously shown in the same tissue samples as those
used for this study [23] that WY-14,643, a potent carcinogen, increased expression of several
base excision DNA repair enzymes, a marker of persistent oxidative damage, in a dose- and
time-dependent manner. At the same time, DEHP, a much less potent carcinogen [29], had
much weaker effect when compared with WY-14,643. Therefore, in this study we measured
the number of 3′OH DNA ends (single-strand breaks) in liver genomic DNA, lesions that may
be generated by DNA damaging agents, endonucleases, or during DNA repair, to further
characterize the effects of WY-14,643 and DEHP on DNA. A 40% increase in [3H]dCTP
incorporation into DNA isolated from the livers of rats fed a WY-14,643-containing diet was
observed (Fig. 6) while DEHP had no effect as compared to control levels.
4. Discussion
Both genotoxic and non-genotoxic environmental agents that can cause liver cancer in rodents
have been shown to lead to changes in DNA methylation and histone modifications [9]. Indeed,
genomic hypomethylation is regarded as one of the causal events in hepatocarcinogenesis
[10,20,40] and several mechanisms, such as the availability of methyl group donors, activity
and/or expression of DNA methyltransferases, increased cell proliferation, and DNA damage,
have been proposed to lead to a progressive loss of DNA methylation [9]. However, even
though time-dependent changes in global and region-specific DNA methylation patterns have
been reported to occur as a result of treatment with classical rodent liver carcinogens [19,41,
42], little is known about the causality of such epigenetic changes.
Our current work shows that long-term (22 weeks) administration of WY-14,643 to rats results
in pronounced changes in DNA methylation, especially in hypomethylation of GC-rich
sequences, in the liver. In contrast, exposure to DEHP had no effect on the methylation status
of hepatic DNA. This data not only demonstrates that WY-14,643 causes loss of DNA
methylation in two species, rat (this study) and mouse [19], which are sensitive to
hepatocarcinogenesis by peroxisome proliferators, but it also suggests that the carcinogenic
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potency of the compounds within this class may be linked to their ability to elicit epigenetic
effects. Currently, there are two identified mechanism by which loss of genomic methylation
may contribute to tumorigenesis. Specifically, (a) loss of DNA methylation may compromise
genomic integrity via chromatin decondensation, the induction of centromere and telomere
abnormalities, chromosome segregation defects [43], and (b) DNA hypomethylation may
promote tumor development by activation and transposition of endogenous retroviral elements
[44,45]. This could result in a variety of genomic instability events including cis-and trans-
insertional mutagenesis, unequal homologous recombination, rearrangements, and segmental
duplications leading to deletions and duplications [32,44,45]. The causal role of these lesions,
as integral part of neoplastic transformation in etiology of cancer, including liver cancer, is
now commonly accepted [46].
The differences in carcinogenic potency among chemicals that belong to a class of peroxisome
proliferators have been studied extensively. While it has been suggested that the extent of
induction of peroxisomes in rodent liver may be a good predictor of hepatocarcinogenesis
[47], it was also shown that the degree of peroxisome proliferation does not correlate well with
tumorigenicity [29]. On the other hand, cell proliferation rates [29], and liver oxidative DNA
damage [23] have been shown to correlate well both with the time, dose and carcinogenic
potency of peroxisome proliferators. Thus, our data which shows profound differences in the
effects on DNA methylation between WY-14,643 and DEHP suggests that epigenetic markers
may also serve to examine the potency of the rodent liver non-genotoxic carcinogens. However,
it should also be noted that while aberrant methylation in tumors may be a useful prognostic
marker in the clinic [10,11], it may not be a sensitive early predictor of the carcinogenicity of
environmental agents in animal studies. Specifically, our data shows lack of effects with DEHP,
a known albeit weaker than WY-14,643 [29] rodent hepatocarcinogen, which suggests that
epigenetic markers alone may be prone to false negative observations.
Importantly, this study also assessed the underlying mechanisms associated with abnormalities
in DNA methylation during peroxisome proliferator-induced hepatocarcinogenesis. Several
studies suggested a link between DNA hypomethylation during carcinogenesis and aberrations
in the intracellular levels of SAM and/or SAH [6,11]. This is especially true for carcinogenesis
associated, at least in part, with alterations in one-carbon metabolism caused by endogenous
(polymorphisms in one-carbon-related genes, or deficiency in vitamin B12/folic acid), or
exogenous (arsenic, etc.) factors. Our data shows that WY-14,643-induced loss of DNA
methylation occurred in the absence of changes in the intracellular levels of SAM and SAH in
the liver. This suggests that loss of genomic methylation during peroxisome proliferator-
induced liver carcinogenesis is not due to lack of availability of methyl donors.
Another crucial factor determining the proper maintenance of DNA methylation patterns is
related to the function of DNA methyltransferases [48]. We show that WY-14,643-induced
global, GC-rich region-specific, and gene-specific hypomethylation of DNA were associated
with a decrease in DNMT1 protein levels, especially relative to DNA replication (i.e.,
concurrent increase in PCNA levels in WY-14,643-treated rats). However, the extensive loss
of DNA methylation detected in the present study is likely not due to a decrease in expression
of DNMT1 alone. This suggestion is supported by the evidence that DNMT1-deficient mice,
despite reductions in DNMT1, are able to maintain normal levels of DNA methylation [49];
however, the ability of DNMT1 to preserve proper methylation status depends on DNA
replication rates [48] and may be disturbed by an elevated cell proliferation, especially under
conditions when integrity of DNA is compromised through DNA damage.
Peroxisome proliferator-induced cell proliferation and oxidative damage to DNA in rodent
liver are thought to be key events in the carcinogenesis mode of action. However, recent
evidence indicates that peroxisome proliferation, cell proliferation and oxidative stress are not
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directly responsible for the development of peroxisome proliferator-induced liver cancer
[50]. Our expected observations that WY-14,643 caused induction of PCNA and lead to an
increase in DNA single-strand breaks suggest that DNA damage, together with increased
proliferation, may have an effect on DNA methylation patterns. DNA damage plays a central
role of in cytosine demethylation [51] and our findings of lower CpG methylation in DNA
from WY-14,643-treated rats indicate that DNA single-strand breaks, in addition to increased
cell proliferation, are essential prerequisites associated with the loss of DNA methylation
during peroxisome proliferator-induced carcinogenesis.
In conclusion, this study provides further evidence that epigenetic alterations are crucial
components in peroxisome proliferator-induced liver carcinogenesis. More importantly, we
show that the degree of hepatic DNA methylation is related to the carcinogenic potential of
the toxicant and is likely a result of accumulating DNA damage, increased cell proliferation
and altered expression of DNA methyltransferase DNMT1.
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Long-term administration of WY-14,643, but not DEHP leads to hypomethylation of genomic
DNA in rat liver. DNA methylation status was assessed in livers of control (white bars), DEHP-
(grey bars), or WY-14,643- (black bars) treated rats using [3H]dCTP extension assay after
digestion of genomic DNA with methylation-sensitive restriction endonuclease HpaII (top
panel), BssHII (middle panel), or AscI (bottom panel) as detailed in Section 2. Data is presented
as mean ± S.D. (n = 5) relative to control for each group and asterisks indicate significant
difference from the age-matched control rats.
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Long-term administration of WY-14,643, but not DEHP, leads to hypomethylation of the
Gstp gene promoter in rat liver. (A) Partial structure of the rat Gstp promoter region extending
from bases +60 to +98 (accession no. L29427) with location of analyzed BstUI, AciI, and HpaII
sites. We reported previously that these sites are methylated in normal liver tissue but lose their
methylation in pre-neoplastic livers and in liver tumors [34]. (B) Methylation-sensitive PCR-
based assay was used to assess site-specific methylation in Gstp promoter region. A decrease
in PCR product recovery after pre-treatment of DNA with restriction enzymes AciI or HpaII
indicates hypomethylation of the promoter, while BstUI site remains methylated.
Representative agarose gel images are shown. (C) Quantitation of the restriction fragments
following digestion with methylation-specific enzymes. Data is presented as mean ± S.D. (n
= 5) relative to control for each group and asterisks indicate significant difference from the
age-matched control rats.
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Trimethylation of histones H3K9 and H4K20 in rat liver is not affected by long-term
administration of WY-14,643 or DEHP. Histone proteins were separated by SDS-PAGE from
livers of control (white bars), DEHP- (A, grey bars), or WY-14,643- (B, black bars) treated
rats and subjected to immunoblotting using specific antibodies against H3Kme3 and
H4K20me3 as detailed in Section 2. Representative Western immunoblot images are shown.
Quantitation of histone trimethylation is presented as mean ± S.D. (n = 5) relative to control
for each group.
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Levels of SAM and SAH in rat liver are note affected by long-term administration of
WY-14,643 or DEHP. SAM and SAH were assessed in livers of control (white bars), DEHP-
(A, grey bars), or WY-14,643- (B, black bars) treated rats as detailed in Section 2. Data is
presented as mean ± S.D. (n = 5) for each group.
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Western blot analysis of DNMT1, PCNA, and c-Myc proteins in the liver of control rats and
rats exposed to DEHP or WY-14,643. Liver tissue lysates were prepared from livers of control
(white bars), DEHP- (grey bars), or WY-14,643-(black bars) treated rats and subjected to
immunoblotting using specific antibodies against DNMT1, PCNA, c-Myc and β-actin as
detailed in Section 2. (A) Representative Western immunoblot images. (B) Quantitative
analysis of the protein levels after normalization to β-actin. Data is presented as mean ± S.D.
(n = 5) relative to control for each group and asterisks indicate significant difference from the
age-matched control rats.
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Effect of long-term administration of WY-14,643 and DEHP on DNA strand breaks in the liver
of control rats and rats exposed to DEHP or WY-14,643. The extent of DNA strand breaks was
measures by assessing the number of 3′OH DNA ends (breaks) in genomic DNA prepared
from livers of control (white bars), DEHP-(grey bars), or WY-14,643- (black bars) treated rats
as detailed in Section 2. Data is presented as mean ± S.D. (n = 5) relative to control for each
group and the asterisk indicates significant difference from the age-matched control group.
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